A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Cancer Research

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Pathology And Forensic Medicine

Show all topics

DOI

10.1158/1078-0432.ccr-12-3349

Other Formats

PDF